All In Biotech

Drug Trial Radar · NCT04265209

[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.

Last checked: Nov 20, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Dec 1, 2021

Primary completion

Aug 2, 2024

Study completion Aug 2, 2024

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
First posted
Feb 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical study to demonstrate an at least equivalent performance of a new PET molecular Imaging radiopharmaceutical named \[18F\] LBT-999 in brain imaging compared to the SPECT reference method named \[123I\]-FP-CIT to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.

Conditions

  • Parkinson Disease
  • Essential Tremor

Interventions

  • SPECTDrug

    \[123I\]-FP-CIT SPECT imaging procedure

  • PETDrug

    \[18F\] LBT-999 PET imaging procedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and specificity by visual analysisTime frame: The independent review committee will analyse the PET and SPECT images blindly. These analyses will be done by batch of 25 patients. Outcome will be assessed at the end of the study, an average of 2 years after first patient in.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Avicenne

    Bobigny, France

  • CHU Bordeaux

    Bordeaux, France

  • Centre Jean PERRIN / Hôpital Gabriel Montpied (CHU)

    Clermont-Ferrand, France

  • Hôpital Henri Mondor

    Créteil, France

  • CLCC Georges-François Leclerc C.G.F.L

    Dijon, France

  • Hôpital Roger Salengro (CHRU de Lille)

    Lille, France

  • Hospices Civils de Lyon

    Lyon, France

  • CHU La Timone

    Marseille, France

  • Hôpital Brabois / Hôpital Central (CHRU Nancy)

    Nancy, France

  • Hôpital Laennec (CHU Nantes)

    Nantes, France

  • Centre Hospitalier Universitaire de Nîmes

    Nîmes, France

  • CHU La Pitié Salpêtrière

    Paris, France

  • Centre Eugène Marquis / CHU Pontchaillou

    Rennes, France

  • Institut de cancérologie Strasbourg Europe

    Strasbourg, France

  • Hôpital Pierre Paul Riquet - Purpan (CHU)

    Toulouse, France

  • CHRU Hôpital Bretonneau

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.